Literature DB >> 7678931

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.

C M Tempany1, A W Partin, E A Zerhouni, S J Zinreich, P C Walsh.   

Abstract

To determine the influence of androgen deprivation induced by the potent 5 alpha-reductase inhibitor finasteride on the volume of the zones of the prostate, 20 symptomatic men with established BPH were randomized to one of three groups: placebo, finasteride 1 mg, and finasteride 5 mg/day. The volume of the entire prostate gland, periurethral zone, and peripheral zone and the seminal vesicles were determined by three dimensional reconstructions of magnetic resonance contoured images of the prostate. There was no significant difference between the results achieved with 1 and 5 mg of finasteride per day; thus the results in these two groups were combined. In the placebo group there was no significant change in the volume of any structure. Following treatment for 1 year with finasteride there was a significant (P < 0.02) 17% decrease in total gland size (11.5 +/- 3.2 cc). Similarly, there was a significant (P < 0.02) 17% decrease in total gland size (11.5 +/- 3.2 cc). Similarly, there was a significant (P < 0.03) decrease in the size of the periurethral zone of the prostate (6.2 +/- 3 cc). Although there was also a decrease in the size of the peripheral zone of the prostate (2.8 +/- 1.2 cc) this did not reach statistical significance. There was no significant change in the volume of the seminal vesicles. These findings indicate for the first time that androgen deprivation induces a significant decrease in the size of the periurethral zone of the prostate in men with established BPH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678931     DOI: 10.1002/pros.2990220106

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

1.  Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.

Authors:  S S Dadras; X Cai; I Abasolo; Z Wang
Journal:  Gene Expr       Date:  2001

Review 2.  MR-guided prostate interventions.

Authors:  Clare Tempany; Sarah Straus; Nobuhiko Hata; Steven Haker
Journal:  J Magn Reson Imaging       Date:  2008-02       Impact factor: 4.813

3.  Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study.

Authors:  Si-Hui Li; Qun-Fang Yang; Pei-Yuan Zuo; Yu-Wei Liu; Yu-Hua Liao; Cheng-Yun Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

Review 4.  Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

Authors:  Matthew Ryan Macey; Mathew C Raynor
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

5.  MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes.

Authors:  Hong Truong; Jennifer Logan; Baris Turkbey; M Minhaj Siddiqui; Soroush Rais-Bahrami; Anthony N Hoang; Chad Pusateri; Brian Shuch; Annerleim Walton-Diaz; Srinivas Vourganti; Jeffrey Nix; Lambros Stamatakis; Colette Harris; Celene Chua; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  Can J Urol       Date:  2013-12       Impact factor: 1.344

Review 6.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

7.  BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.

Authors:  Feng Li; Laura E Pascal; Jianhua Zhou; Yibin Zhou; Ke Wang; Anil V Parwani; Rajiv Dhir; Peng Guo; Dalin He; Joel B Nelson; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2018-02-05

Review 8.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

Review 9.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 10.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.